RaineA.E., RogerS.D.Effects of erythropoietin on blood pressure.Am J Kidney Dis1991; 18: 76–83.
2.
LindeT., SandhagenB., BrattebyL.E., de VerdierC.H., DanielsonB.G., WikstromB.Reduced oxygen affinity contributes to improved oxygen releasing capacity during erythropoietin treatment of renal anaemia.Nephrol Dial Transplant1993; 8: 524–9.
3.
LindeT., SandhagenB., HaggA., MorlinC., WikstromB., DanielsonB.G.Blood viscosity and peripheral vascular resistance in patients with untreated essential hypertension.J Hypertens1993; 11: 731–6.
4.
RogerS.D., BakerL.R., RaineA.E.Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).Clin Nephrol1993; 39: 103–10.
5.
CarliniR., ObialoC.I., RothsteinM.Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.Am J Hypertens1993; 6: 103–7.
6.
CarliniR.G., DussoA.S., ObialoC.I., AlvarezU.M., RothsteinM.Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells.Kidney Int1993; 43: 1010–14.
